20 COMMERCE DRIVE, SUITE 135, CRANFORD, NJ
Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value
Amended material disclosure
Viskase Holdings Enters Seventh Amendment to Credit Agreement
Grant Thornton Appointed as Independent Auditor for Viskase Holdings Inc.
Appointment of Michael Blecic as Chief Financial Officer
Enzon Pharmaceuticals Completes Exchange Offer for Series C Preferred Stock
Announces Reverse Stock Split
Enzon Pharmaceuticals Extends Exchange Offer for Series C Preferred Stock
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2023
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Registration of Securities under Section 12(g)
Amended Tender Offer Statement by Issuer
Amended Registration of Securities under Section 12(g)